Bridgeway Capital Management Inc. boosted its holdings in shares of Neos Therapeutics Inc (NASDAQ:NEOS) by 41.6% in the third quarter, HoldingsChannel.com reports. The fund owned 170,100 shares of the company’s stock after buying an additional 50,000 shares during the quarter. Bridgeway Capital Management Inc.’s holdings in Neos Therapeutics were worth $825,000 at the end of the most recent quarter.
Other institutional investors and hedge funds have also added to or reduced their stakes in the company. Trexquant Investment LP acquired a new position in shares of Neos Therapeutics in the 2nd quarter valued at $131,000. Schwab Charles Investment Management Inc. grew its holdings in shares of Neos Therapeutics by 28.6% in the 2nd quarter. Schwab Charles Investment Management Inc. now owns 56,200 shares of the company’s stock valued at $352,000 after buying an additional 12,500 shares during the period. Canada Pension Plan Investment Board acquired a new position in shares of Neos Therapeutics in the 2nd quarter valued at $469,000. Millennium Management LLC acquired a new position in shares of Neos Therapeutics in the 1st quarter valued at $519,000. Finally, JPMorgan Chase & Co. grew its holdings in shares of Neos Therapeutics by 162.5% in the 3rd quarter. JPMorgan Chase & Co. now owns 267,417 shares of the company’s stock valued at $1,297,000 after buying an additional 165,555 shares during the period. 45.12% of the stock is owned by hedge funds and other institutional investors.
Several equities analysts have recently issued reports on the stock. Wells Fargo & Co decreased their price target on shares of Neos Therapeutics from $11.00 to $6.00 and set an “outperform” rating for the company in a report on Wednesday, November 14th. Zacks Investment Research lowered shares of Neos Therapeutics from a “hold” rating to a “sell” rating in a report on Wednesday, November 14th. JMP Securities decreased their price target on shares of Neos Therapeutics from $22.00 to $10.00 and set a “market outperform” rating for the company in a report on Monday, November 12th. Cantor Fitzgerald reissued a “buy” rating and issued a $20.00 price target on shares of Neos Therapeutics in a report on Friday, November 9th. Finally, ValuEngine raised shares of Neos Therapeutics from a “sell” rating to a “hold” rating in a report on Monday, September 24th. One research analyst has rated the stock with a sell rating, three have assigned a hold rating and three have assigned a buy rating to the company’s stock. The stock currently has a consensus rating of “Hold” and an average target price of $12.00.
In related news, Director Alan L. Heller acquired 43,478 shares of the business’s stock in a transaction that occurred on Thursday, November 8th. The shares were acquired at an average cost of $2.30 per share, with a total value of $99,999.40. The purchase was disclosed in a legal filing with the SEC, which is available at this link. Insiders own 5.40% of the company’s stock.
NEOS opened at $2.00 on Friday. The firm has a market capitalization of $62.02 million, a P/E ratio of -0.75 and a beta of 0.34. Neos Therapeutics Inc has a 12 month low of $1.65 and a 12 month high of $11.69.
Neos Therapeutics (NASDAQ:NEOS) last posted its quarterly earnings data on Friday, November 9th. The company reported ($0.43) EPS for the quarter, missing the consensus estimate of ($0.40) by ($0.03). The company had revenue of $12.50 million during the quarter, compared to the consensus estimate of $14.80 million. Neos Therapeutics had a negative net margin of 133.46% and a negative return on equity of 586.25%. On average, equities analysts predict that Neos Therapeutics Inc will post -1.71 earnings per share for the current fiscal year.
Neos Therapeutics Company Profile
Neos Therapeutics, Inc, a pharmaceutical company, develops, manufactures, and commercializes products for the treatment of attention deficit hyperactivity disorder (ADHD) using its drug delivery technology platform. Its product candidates are extended-release (XR) medications in orally disintegrating tablets or liquid suspension dosage forms.
See Also: Compound Interest
Want to see what other hedge funds are holding NEOS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Neos Therapeutics Inc (NASDAQ:NEOS).
Receive News & Ratings for Neos Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neos Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.